6.850USD-6.83%Mkt Cap: —P/E: —1d ago
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally…
Industry Peers
Software - ApplicationKey Statistics
Company
Market Cap—
Enterprise Value561.09M $
Revenue (TTM)87.53M $
Gross Profit76.71M $
Net Income (TTM)-202.70M $
Revenue/Share0.9850 USD
Last Price6.850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees102
CountryGB
SectorTechnology
IndustrySoftware - Application
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.54
EV/Revenue6.41
P/S—
P/B12.07
EPS (TTM)-0.41
EPS (Forward)—
52W Range
6.8005% of range7.720
52W High7.720 USD
52W Low6.800 USD
Profitability
Gross Margin87.64%
Oper. Margin-81.62%
EBITDA Margin-181.26%
Profit Margin-231.59%
ROE-471.16%
ROA-49.59%
Growth
Revenue Growth1775.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-162.20M $
CapEx (TTM)—
FCF Margin-118.17%
FCF Yield—
Net Debt-52.02M $
Net Debt/EBITDA0.33
Balance Sheet
Debt/Equity168.71
Current Ratio2.25
Quick Ratio2.12
Book Value/Sh0.5520 USD
Cash/Share1.506 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.083333:1
Split DateJun 1, 2023
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.73.74M
Float70.57M
Insiders0.90%
Institutions110.61%
Technical
SMA 509.963 (-31.2%)
SMA 2008.966 (-23.6%)
Beta0.29
S&P 52W Chg18.16%
Avg Vol (30d)2.67K
Avg Vol (10d)125
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—